SVB Leerink upgraded NextGen Healthcare from Mkt Perform to Outperform and set a new price target of $22.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/28/2023 | $21.00 | Overweight | Cantor Fitzgerald |
| 4/12/2023 | $24.00 | Overweight | Stephens |
| 10/21/2022 | $20.00 | Neutral | Piper Sandler |
| 9/7/2022 | $20.00 | Hold | Truist |
| 5/6/2022 | $26.00 | Neutral → Buy | Guggenheim |
| 4/14/2022 | Neutral | Guggenheim | |
| 1/6/2022 | $22.00 | Mkt Perform → Outperform | SVB Leerink |
| 1/6/2022 | Market Perform → Outperform | SVB Leerink |
Cantor Fitzgerald initiated coverage of NextGen Healthcare with a rating of Overweight and set a new price target of $21.00
Stephens initiated coverage of NextGen Healthcare with a rating of Overweight and set a new price target of $24.00
Piper Sandler resumed coverage of NextGen Healthcare with a rating of Neutral and set a new price target of $20.00
15-12G - NEXTGEN HEALTHCARE, INC. (0000708818) (Filer)
S-8 POS - NEXTGEN HEALTHCARE, INC. (0000708818) (Filer)
S-8 POS - NEXTGEN HEALTHCARE, INC. (0000708818) (Filer)
NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal second quarter ending September 30, 2023. Fiscal 2024 Second Quarter Highlights Total revenue was $176.4 million compared to $159.4 million for the same period a year ago, an increase of 10.6%. Recurring revenue was $161.3 million compared to $143.5 million for the same period a year ago, an increase of 12.4%. Non-recurring revenue was $15.1 million compared to $15.9 million for the same period a year ago, a decrease of 5.3%. Fully diluted net income per share was $0.07 compared to $0.20 for the same period
Attendees will Engage with Technology and Learn Best Practices for Maximizing Outcomes NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, will host a gathering of ambulatory healthcare professionals from around the country at UGM23. The user group meeting will be held November 29 - December 2, 2023, at Rosen Shingle Creek in Orlando, Florida. Approximately 2,000 attendees are expected to attend and engage with the latest healthcare technology solutions, learn from industry leaders and connect with peers. Themed "Maximize Outcomes," UGM23 will offer expert and client-led seminars on navigating regulatory challenges, opti
Fully Automated Ambient Listening Solution Summarizes Patient Visits Directly into EHR NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced the availability of NextGen™ Ambient Assist, an ambient listening solution that interprets patient-provider conversations in real time to summarize appointments and document care plans at unprecedented speeds. Ambient Assist delivers AI-generated subjective, objective, assessment, and plan (SOAP) notes directly into the electronic health record (EHR) for provider convenience. SOAP notes have long been used in many specialties to help providers organize their observatio
4 - NEXTGEN HEALTHCARE, INC. (0000708818) (Issuer)
4 - NEXTGEN HEALTHCARE, INC. (0000708818) (Issuer)
4 - NEXTGEN HEALTHCARE, INC. (0000708818) (Issuer)
SC 13G/A - NEXTGEN HEALTHCARE, INC. (0000708818) (Subject)
SC 13G - NEXTGEN HEALTHCARE, INC. (0000708818) (Subject)
SC 13G/A - NEXTGEN HEALTHCARE, INC. (0000708818) (Subject)
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Structure Therapeutics Inc. (NASDAQ:GPCR) Structure Therapeutics recently released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overw
NextGen Healthcare (NASDAQ:NXGN) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.25 by 24 percent. This is a 24 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $176.42 million which missed the analyst consensus estimate of $176.95 million by 0.30 percent. This is a 10.65 percent increase over sales of $159.44 million the same period last year.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70. Here’s the latest list of major overbought players in this sector. Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Orchestra BioMed was granted FDA approval of an investigational device exemption to initiate its global BACKBEAT study evaluating
Health industry experts to provide counsel amid company's rapid growth and broader telemental health adoption Brightside Health, a telehealth platform that delivers life-changing mental health care to individuals with mild-to-severe clinical depression, anxiety, and other mood disorders, announced today the appointment of health industry experts Jeff Margolis as an independent board member and The Honorable David Shulkin, MD, as an advisor, effective October 1, 2022. Margolis and Secretary Shulkin will provide guidance to the organization as it expands and continues to deliver life-changing mental healthcare to all who need it, including those with elevated suicide risk. "We're pleased to
Industry veteran brings longstanding track record of growing innovative healthcare technology and service organizations from early-stage startup through category leadership DNAnexus, Inc., the leader in biomedical informatics and data management, today announced the appointment of Jeff Margolis, a seasoned healthcare information technology executive and current Senior Advisor for Blackstone (NYSE:BX), to its Board of Directors. The appointment follows the company's $200 million financing round, which was led by Blackstone. "DNAnexus is already an exciting company at the intersection of healthcare and life sciences and the recent Blackstone investment will support the goal of becoming a ca
Julien Mininberg, Jaymin Patel and Pamela Puryear, Ph.D., Bring Significant Technology, Distribution, Consumer Brand and Human Resources Expertise Food solutions company SpartanNash (the "Company") (NASDAQ:SPTN) today announced that, following a comprehensive board refreshment process, three new independent directors, Julien Mininberg, Jaymin Patel and Pamela Puryear, Ph.D., have been appointed to the Company's Board of Directors (the "Board"), effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220207005303/en/Julien Mininberg (Photo: Business Wire) "Since last summer, our Board has undertaken a deliberate and
Raises Midpoint of Fiscal 2024 Revenue Guidance Range NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal first quarter ending June 30, 2023. Fiscal 2024 First Quarter Highlights Total revenue was $178.2 million compared to $153.3 million for the same period a year ago, an increase of 16.2%. Recurring revenue was $163.4 million compared to $139.8 million for the same period a year ago, an increase of 16.9%. Non-recurring revenue was $14.8 million compared to $13.5 million for the same period a year ago, an increase of 9.5%. Fully diluted net income per shar
NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative cloud-based healthcare technology solutions, today announced that it will release its fiscal 2024 first quarter results on Monday, July 24, 2023, after market close. In conjunction, the company will host a conference call to discuss the results and provide an update on its operations and strategy at 5 p.m. EST the same day. Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 800-343-4136 or 203-518-9843 for international callers and referencing participant code NXGNQ124 approximately 15 minutes prior to the call. A recording of the event will be available at inv
NextGen Healthcare, Inc. (NASDAQ:NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced its operating results for the fiscal fourth quarter and year ended March 31, 2023. Fiscal 2023 Fourth Quarter Highlights Total revenue was $178.6 million compared to $151.3 million for the same period a year ago, an increase of 18.0%. Recurring revenue was $161.9 million compared to $137.2 million for the same period a year ago, an increase of 18.0%. Non-recurring revenue was $16.6 million compared to $14.0 million for the same period a year ago, an increase of 18.4%. Fully diluted net loss per share was $0.38, which includes an accrual for the